Additionally, TP53 mutations have been associated with more aggressive disease (24–26), which may in part explain why we are observing TP53 mutations more often than expected in primary prostate cancer in this cohort of patients who all had lethal forms of the disease, even if many presented as localized tumors. This evidence concerns the gene TP53 and prostate carcinoma.